Skip to main content

Advertisement

Table 2 ED 50s & 90s of Doxovir™ to Adenovirus Type 5. Effective dose (ED) 50s and 90s of Doxovir™ (CTC-96) against Adenovirus type 5 in HeLa (human cervical carcinoma), A549 (human cervical carcinoma) and SIRC (rabbit corneal) cells during Virucidal, Antiviral and Viral Inactivation assays.

From: Efficacy of topical cobalt chelate CTC-96 against adenovirus in a cell culture model and against adenovirus keratoconjunctivitis in a rabbit model

   (MIC 50 (μg/ml) (MIC 90 (μg/ml)
HeLa (human cervical carcinoma) Virucidal 33.0 ± 6.9 46.6 ± 9.7
  Antiviral 4.5 ± 0.1 21.8 ± 1.2
  Viral Inactivation 16.5 ± 2.5 43.0 ± 1.3
A549 (human lung carcinoma) Virucidal 31.7 ± 1.9 46.3 ± 2.6
  Antiviral 4.7 ± 0.2 20.8 ± 1.9
  Viral Inactivation 4.2 ± 1.1 37.5 ± 6.5
SIRC (rabbit cornea) Virucidal 13.6 ± 2.3 22.7 ± 3.5
  Antiviral 27.3 ± 8.3 45.5 ± 1.6
  Viral Inactivation 13.1 ± 2.9 23.9 ± 4.9